- Products & Services
- Quality & Environmental Policy
- Corporate Profile
- Feb.17,2020
- LSI Medience Launches Testing for Novel Coronavirus
- Aug.1,2019
- Announcement of Shareholder Change
- July.19,2019
- LSI Medience Joins the Global Diagnostics Network (GDN)
- May.14,2019
- Notice Regarding “Life Science Institute Reaches Agreement on Strategic Capital Partnership with PHC Holdings” Announced by Life Science Institute, Inc.
- May.4,2018
- Initiation of a Japanese Cancer Patient-derived Xenograft (J-PDX) Repository Establishment Program
- Aug.3,2017
- Provision of the first centralized clinical laboratory testing service in the Philippines
- May.2,2014
- Announcement of Business Alliance between Nikon and LSI Medience
- Feb.6,2014
- Mitsubishi Chemical Medience Corporation Announces New Company Name and New Head Office
- Sep.17,2013
- Mitsubishi Chemical Medience Starts Up Evaluating the Usefulness of Glycomics Analysis Services for Glycosylated Biologics and Biosimilars - Mitsubishi Chemical Medience Enters into an Exclusive License Agreement of Energy Resolved Oxonium Ion Monitoring (Erexim) Technology -
- Jun.21,2013
- Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
- Oct.31,2011
- Mitsubishi Chemical Medience Corporation launches PATHFAST Analyzer in U.S. market
- Jun.17,2011
- Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST cTnI-II (cardiac Troponin I) Test in U.S.
We provide IVD instruments & reagents , clinical Testing & services.
Central laboratory, bio-analysis services and evaluating the safety of chemicals.
We offer a series of safety, pharmacology, and pharmacokinetic studies from discovery of pharmaceutical products and regenerative medicines to approval application.
As the GLP-compliant certification authority, we provide application services and safety studies of chemical substance.
